Skip Nav Destination
Issues
1 January 2020
-
Cover Image
Cover Image
Chimeric antigen receptor T (CAR T) cells represent a new paradigm in cancer therapy. However, viral-based production of these CAR T cells is laborious and comes at a high cost. Therefore, Cai and colleagues sought to utilize minicircle DNA (mcDNA) to produce CAR T cells without the need for viruses. In the cover image, the authors demonstrate strong expression of PSCA on a prostate xenograft. CAR T cells derived using mcDNA targeted at this PSCA infiltrated the tumor and increased cytokine secretion. Read the article on page 178. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Author Choice
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches; Antonio G. Trinidad; Gareth Hughes; Gemma N. Jones; Adina M. Hughes; Andrew G. Thomason; Paul Gavine; Andy Cui; Stephanie Ling; Jonathan Stott; Roger Clark; Samantha Peel; Pendeep Gill; Louise M. Goodwin; Aaron Smith; Kurt G. Pike; Bernard Barlaam; Martin Pass; Mark J. O'Connor; Graeme Smith; Elaine B. Cadogan
Author Choice
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
Antje M. Wengner; Gerhard Siemeister; Ulrich Lücking; Julien Lefranc; Lars Wortmann; Philip Lienau; Benjamin Bader; Ulf Bömer; Dieter Moosmayer; Uwe Eberspächer; Sven Golfier; Christoph A. Schatz; Simon J. Baumgart; Bernard Haendler; Pascale Lejeune; Andreas Schlicker; Franz von Nussbaum; Michael Brands; Karl Ziegelbauer; Dominik Mumberg
Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Hilary A. Kenny; Madhu Lal-Nag; Min Shen; Betul Kara; Dominik A. Nahotko; Kristen Wroblewski; Sarah Fazal; Siquan Chen; Chun-Yi Chiang; Yen-Ju Chen; Kyle R. Brimacombe; Juan Marugan; Marc Ferrer; Ernst Lengyel
Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Xiaoyun Tang; Melinda Wuest; Matthew G.K. Benesch; Jennifer Dufour; YuanYuan Zhao; Jonathan M. Curtis; Alain Monjardet; Bertrand Heckmann; David Murray; Frank Wuest; David N. Brindley
A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Zhenyu Yang; Dan Wang; James K. Johnson; Laura E. Pascal; Keita Takubo; Raghunandan Avula; Anish Bhaswanth Chakka; Jianhua Zhou; Wei Chen; Mingming Zhong; Qiong Song; Hui Ding; Zeyu Wu; Uma R. Chandran; Taber S. Maskrey; Joel B. Nelson; Peter Wipf; Zhou Wang
Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage
Amrita Salvi; Chiraz Soumia M. Amrine; Julia R. Austin; KiAundra Kilpatrick; Angela Russo; Daniel Lantvit; Esther Calderon-Gierszal; Zachary Mattes; Cedric J. Pearce; Mark W. Grinstaff; Aaron H. Colby; Nicholas H. Oberlies; Joanna E. Burdette
Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo
Amber L. Fifield; Paul D. Hanavan; Douglas O. Faigel; Eduard Sergienko; Andrey Bobkov; Nathalie Meurice; Joachim L. Petit; Alysia Polito; Thomas R. Caulfield; Erik P. Castle; John A. Copland; Debabrata Mukhopadhyay; Krishnendu Pal; Shamit K. Dutta; Huijun Luo; Thai H. Ho; Douglas F. Lake
Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
May Elbanna; Ashley R. Orillion; Nur P. Damayanti; Remi Adelaiye-Ogala; Li Shen; Kiersten Marie Miles; Sreenivasulu Chintala; Eric Ciamporcero; Swathi Ramakrishnan; Sheng-yu Ku; Karen Rex; Sean Caenepeel; Angela Coxon; Roberto Pili
Large Molecule Therapeutics
Author Choice
Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Dina V. Hingorani; Matthew K. Doan; Maria F. Camargo; Joseph Aguilera; Seung M. Song; Donald Pizzo; Daniel J. Scanderbeg; Ezra E.W. Cohen; Andrew M. Lowy; Stephen R. Adams; Sunil J. Advani
Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Barbara Akla; Matthieu Broussas; Noureddine Loukili; Alain Robert; Charlotte Beau-Larvor; Martine Malissard; Nicolas Boute; Thierry Champion; Jean-Francois Haeuw; Alain Beck; Michel Perez; Cyrille Dreyfus; Mariya Pavlyuk; Eric Chetaille; Nathalie Corvaia
Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Toshihiro Kushibiki; Toru Nakamura; Masumi Tsuda; Takahiro Tsuchikawa; Koji Hontani; Kazuho Inoko; Mizuna Takahashi; Toshimichi Asano; Keisuke Okamura; Soichi Murakami; Yo Kurashima; Yuma Ebihara; Takehiro Noji; Yoshitsugu Nakanishi; Kimitaka Tanaka; Nako Maishi; Katsunori Sasaki; Woong-Ryeon Park; Toshiaki Shichinohe; Kyoko Hida; Shinya Tanaka; Satoshi Hirano
Cancer Biology and Translational Studies
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2−/− Ovarian Cancer Cells
Lu Liu; Shurui Cai; Chunhua Han; Ananya Banerjee; Dayong Wu; Tiantian Cui; Guozhen Xie; Junran Zhang; Xiaoli Zhang; Eric McLaughlin; Ming Yin; Floor J. Backes; Arnab Chakravarti; Yanfang Zheng; Qi-En Wang
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
Vindhya Udhane; Cristina Maranto; David T. Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G. Talati; Anjishnu Banerjee; Kenneth A. Iczkowski; Kenneth Jacobsohn; William A. See; Tuomas Mirtti; Deepak Kilari; Marja T. Nevalainen
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models
Walid S. Kamoun; Anne-Sophie Dugast; James J. Suchy; Stephanie Grabow; Ross B. Fulton; James F. Sampson; Lia Luus; Michael Santiago; Alexander Koshkaryev; Gang Sun; Vasileios Askoxylakis; Eric Tam; Zhaohua Richard Huang; Daryl C. Drummond; Andrew J. Sawyer
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Heather M. Moore; Heidi M. Savage; Carol O'Brien; Wei Zhou; Ethan S. Sokol; Michael E. Goldberg; Ciara Metcalfe; Lori S. Friedman; Mark R. Lackner; Timothy R. Wilson
Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Usha Malhotra; Sarbajit Mukherjee; Christos Fountzilas; Patrick Boland; Austin Miller; Santosh Patnaik; Kristopher Attwood; Sai Yendamuri; Araba Adjei; Eric Kannisto; Mateusz Opyrchal; Peter Bushunow; Peter Loud; Renuka Iyer; Nikhil Khushalani
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Jaume Capdevila; Ignacio Matos; Francesco M. Mancuso; Carmela Iglesias; Paolo Nuciforo; Carles Zafon; Hector G. Palmer; Zighereda Ogbah; Laura Muiños; Jorge Hernando; Guillermo Villacampa; Carol E. Peña; Josep Tabernero; Marcia S. Brose; Martin Schlumberger; Ana Vivancos
Acknowledgment to Reviewers
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.